Isoprinosin, tablets 500 mg 50 pcs.

treatment of influenza and other acute respiratory infections;
infections caused by Herpes simplex virus types 1, 2, 3 and 4: genital and labial herpes, herpetic keratitis, shingles, varicella, infectious mononucleosis caused by Epstein-Barr virus;
cytomegalovirus infection;
measles of severe course;
papillomavirus infection: papillomas of the larynx/vocal cords (fibrous type), genital papillomavirus infection in men and women, warts;
molluscum contagiosum;
subacute sclerosing panencephalitis.

Indications

treatment of influenza and other acute respiratory viral infections;
infections caused by the Herpes simplex virus types 1, 2, 3 and 4: genital and labial herpes, herpetic keratitis, herpes zoster, chicken pox, infectious mononucleosis caused by the Epstein-Barr virus;
cytomegalovirus infection;
severe measles;
papillomavirus infection: papillomas of the larynx/vocal cords (fibrous type), papillomavirus infection of the genitals in men and women, warts;
molluscum contagiosum;
subacute sclerosing panencephalitis.

Special instructions

Isoprinosine, like other antiviral drugs, is most effective for acute viral infections if treatment is started at an early stage of the disease (preferably from the first day of the disease).
After two weeks of using the drug, the concentration of uric acid in the blood serum and urine should be monitored.
Also, with long-term use, it is recommended to periodically monitor the concentration of uric acid in the blood serum and urine.
Patients with significantly increased concentrations of uric acid in the body can simultaneously take medications that lower their concentrations.
It is necessary to monitor the concentration of uric acid in the blood serum when prescribing the drug simultaneously with drugs that increase the concentration of uric acid or drugs that impair renal function.
With long-term use, after four weeks of use, it is advisable to monitor liver and kidney function every month (transaminase activity, level of creatinine, uric acid in the blood plasma).
The drug should be used with caution in patients with acute liver failure as it is metabolized by the liver.
Impact on the ability to drive vehicles and machinery
The effect of isoprinosine on the psychomotor functions of the body and on the ability to drive vehicles and moving machinery has not been studied.
When using the drug, the possibility of dizziness and drowsiness should be taken into account.

Active ingredient

Inosine Pranobex

Composition

1 tablet contains:
active ingredient: inosine pranobex (isoprinosine) – 500 mg;
excipients: mannitol 67.0 mg, wheat starch 67.0 mg, povidone K 30 10.0 mg, magnesium stearate 6.0 mg.

Pregnancy

Pregnancy
The drug is contraindicated during pregnancy, as the safety of use has not been studied.
Breastfeeding period
There are no data on the excretion of isoprinosine or its metabolites into breast milk. A risk to the infant cannot be excluded. During treatment with the drug, breastfeeding should be stopped.
Fertility
There is no data on the effect of the drug on human fertility. Animal studies have shown no effect on fertility.

Contraindications

hypersensitivity to the components of the drug;
gout;
urolithiasis;
arrhythmias;
chronic renal failure;
children under 3 years of age (body weight up to 15-20 kg);
pregnancy and breastfeeding period.

With caution
Caution should be exercised when prescribing isoprinosine simultaneously with drugs – xanthine oxidase inhibitors, diuretics, zidovudine, in case of acute liver failure.

Interaction

Immunosuppressants weaken the immunostimulating effect of the drug.
Isoprinosine should be used with caution in patients taking concomitant xanthine oxidase inhibitors (for example, allopurinol) or uricosurics, including thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide) or loop diuretics (furosemide, torasemide, ethacrynic acid), as this may result in increased serum uric acid concentrations.
The combined use of the drug with zidovudine leads to an increase in the concentration of the latter in the blood plasma and lengthens its half-life (when used together, a dose adjustment of zidovudine may be required).

Overdose

In case of overdose, gastric lavage and symptomatic therapy are indicated.

Storage conditions

Store at a temperature not exceeding 25 °C.
Keep out of the reach of children!

Shelf life

5 years.
Do not use after expiration date.

Manufacturer

Luzomedicamenta Sociedad Tecnica Pharmaceutica, Portugal